Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiquimod - 3M Pharmaceuticals

Next Previous
Drug Profile

Imiquimod - 3M Pharmaceuticals

Alternative Names: Aldara; Beselna Cream 5%; DZ 2636; MTD-39; R 837; S 26308; Vyloma; Zyclara

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Maastricht University; Meda; Medicis Pharmaceutical Corporation; Mochida Pharmaceutical
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Genital warts; Herpes simplex virus infections
  • No development reported Cervical intraepithelial neoplasia; Molluscum contagiosum; Photodamage; Tinea pedis; Vulvar intraepithelial neoplasia
  • Discontinued Hepatitis B; Hepatitis C; HIV infections; Warts

Most Recent Events

  • 11 Nov 2019 The Scottish Medicines Consortium recommends imiquimod for Actinic keratosis in Scotland
  • 09 Jul 2019 No development reported - Phase-III for Cervical intraepithelial neoplasia in Netherlands (Topical)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top